Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD), a medical technology firm, announced that CEO Faz Chowdhury, Ph.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled virtually from September 13 – 15, 2021. The corporate presentation will be available starting September 13 at 7:00 AM ET. Investors can register for the conference on the official website. Nemaura specializes in non-invasive diagnostic devices, including sugarBEAT®, a CE-approved continuous glucose monitor, and proBEAT™, an AI-driven health service.

Loughborough, England, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the H.C. Wainwright 23^rd Annual Global Investment Conference, which is being held virtually from September 13 – 15, 2021.

Dr. Chowdhury will deliver his corporate presentation, which will become available beginning on September 13 at 7:00 AM ET.

Investors can register here: www.hcwevents.com.

Mr. Chowdhury will also be available for one-on-one meetings throughout the conference.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When will Nemaura Medical present at the H.C. Wainwright Conference?

Nemaura Medical will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to 15, 2021.

What is the focus of Nemaura Medical's presentation at the conference?

CEO Faz Chowdhury will deliver a corporate presentation focused on Nemaura's non-invasive wearable diagnostic devices.

What products is Nemaura Medical currently commercializing?

Nemaura Medical is commercializing sugarBEAT®, a continuous glucose monitor, and proBEAT™, a digital health service.

What significant markets does Nemaura Medical operate in?

Nemaura Medical operates in the Type 2 diabetes market, the pre-diabetic market, and the wearable health-tech sector.

How can investors register for the H.C. Wainwright Conference?

Investors can register for the conference by visiting the H.C. Wainwright events website.